FIGURE 13.

L-PGDS promotes glial cell migration through MARCKS and AKT-RhoA-JNK. Mixed glial cells were treated with recombinant L-PGDS protein (100 ng/ml) in the presence of 1L6-hydroxymethyl-chiroinositol-2-(R)-2-O-methyl-3-O-octadecyl-sn-glycerocarbon (AKT-specific inhibitor, 5 μm), C3 transferase (RhoA-specific inhibitor, 0.2 μg/ml), or SP600125 (JNK-specific inhibitor, 5 μm), and then wound healing assay was done to evaluate cell migration (A). The results are the mean ± S.D. (n = 3). *, p < 0.05; compared with the treatments without inhibitors. Alternatively, mixed glial cells were transfected with control siRNA or Marcks siRNA. After 48 h, transfected cells were incubated with L-PGDS protein (100 ng/ml), and the Boyden chamber assay was done to evaluate cell migration after 24 h (B). The results are the mean ± S.D. (n = 3). *, p < 0.05. The efficiency of Marcks knockdown by siRNA was confirmed by RT-PCR analysis (C). GAPDH was used as an internal control.